Premium
Effects of aspirin on serum C‐reactive protein and interleukin‐6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo‐controlled crossover trial
Author(s) -
Hovens M. M. C.,
Snoep J. D.,
Groeneveld Y.,
Frölich M.,
Tamsma J. T.,
Huisman M. V.
Publication year - 2008
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2007.00794.x
Subject(s) - aspirin , placebo , medicine , diabetes mellitus , type 2 diabetes , crossover study , gastroenterology , c reactive protein , inflammation , randomized controlled trial , endocrinology , pathology , alternative medicine
Aim: Low‐grade inflammation plays a pivotal role in atherogenesis in type 2 diabetes. Next to its antithrombotic effects, several lines of evidence demonstrate anti‐inflammatory properties of aspirin. We determined the effects of aspirin on inflammation – represented by C‐reactive protein (CRP) and interleukin‐6 (IL‐6) – in type 2 diabetic subjects without cardiovascular disease and assessed differential effects of aspirin 300 mg compared with 100 mg. Methods: A randomized, placebo‐controlled, double‐blind, crossover trial was performed in 40 type 2 diabetic patients. In two periods of 6 weeks, patients used 100 or 300 mg aspirin and placebo. Plasma CRP and IL‐6 levels were measured before and after both periods. Results: Use of aspirin resulted in a CRP reduction of 1.23 ± 1.02 mg/l (mean ± s.e.m.), whereas use of placebo resulted in a mean increase of 0.04 ± 1.32 mg/l ( P = 0.366). Aspirin reduced IL‐6 with 0.7 ± 0.5 pg/ml, whereas use of placebo resulted in a mean increase of 0.2 ± 0.8 pg/ml ( P = 0.302). There were no significant differences in effects on CRP and IL‐6 between 100 and 300 mg aspirin. Conclusions: Our results indicate that a 6‐week course of aspirin does not improve low‐grade inflammation in patients with type 2 diabetes without cardiovascular disease, although a modest effect could not be excluded. No significant differential effects between aspirin 100 and 300 mg were found.